UNITAID Rejected Three Truscreen Grant Proposals
The health technology firm continues to pursue four other grant applications as it expands in Africa.
Updated on Sept. 23, 2026 in Cancer

Live Poll
Should private companies rely on international grant funding to expand access to medical technologies?
UNITAID has declined three grant proposals submitted by Truscreen Group Limited in April 2026. The company remains engaged in other active applications intended to support cervical cancer screening efforts in low and middle income countries.
Why it matters
These grant proposals were part of a broader effort to secure funding for cervical cancer elimination initiatives. Despite the recent rejections, the company maintains active partnerships and clinical trials aimed at expanding access to its technology.
Nigeria faces an estimated cervical cancer burden of 23.9 cases per 100,000 women annually, significantly higher than the global average of 12.4 per 100,000. A clinical evaluation involving 300 patients is currently underway in the country.
The players
Truscreen Group Limited
This health technology company specializes in cervical cancer screening devices designed for use in low-resource settings.
UNITAID
This global health organization works to identify and fund innovative solutions to prevent, diagnose, and treat major diseases in low and middle income countries.
Clinton Health Access Initiative
This global health organization works to strengthen health systems and increase access to life-saving medicines and diagnostics.
National AIDS Council of Zimbabwe
This government entity coordinates the national response to HIV and AIDS programs throughout Zimbabwe.
Zerocancer Professional Consult Limited
This firm serves as the appointed distributor for medical technology products in Nigeria, Ghana, and Côte d'Ivoire.
The details
Truscreen continues to participate in a grant application led by a global NGO that includes the Clinton Health Access Initiative. Meanwhile, the company is awaiting regulatory product approval in Nigeria, which is expected within the next 3 to 6 months.
Timeline
Formal partnership established with National AIDS Council of Zimbabwe in 2022.
Three grant proposals submitted to UNITAID in April 2026.
UNITAID notified Truscreen of proposal rejection in September 2026.
Expected announcement of four live grant applications by December 31, 2026.
The Big Picture
This outcome follows a pattern set by the UNITAID cervical cancer elimination initiative regarding the scaling of new diagnostic technologies in developing nations. The decision reflects the rigorous vetting processes applied to health tech deployments in low and middle income countries.
The progress of these clinical evaluations and regulatory approvals determines whether patients in Nigeria will gain access to new cervical cancer screening options. Successful implementation could significantly reduce the local mortality rate of 14.1 deaths per 100,000 women.
The takeaway
Securing international grant funding is a critical component for companies looking to deploy health technology in resource-limited settings. Organizations must often manage multiple concurrent applications while navigating complex regulatory environments to reach patients effectively.
What happens next
Results for four live grant applications involving Truscreen are expected to be announced by December 31, 2026.
Further reading
Learn more about the latest developments in Cancer research and screening technologies.
Source note: This article includes information reported by Sharechat.
Live Poll
Should private companies rely on international grant funding to expand access to medical technologies?



